Costimulatory molecules as vaccine adjuvants: to 4-1BB or not to 4-1BB?
作者信息
Rahman Khalidur, Iyer Smita S
机构信息
Division of Digestive Diseases, School of Medicine, Emory University, Atlanta, GA, USA.
Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
出版信息
Cell Mol Immunol. 2015 Jul;12(4):508-9. doi: 10.1038/cmi.2014.90. Epub 2014 Sep 8.
Abstract
摘要
相似文献
1
Costimulatory molecules as vaccine adjuvants: to 4-1BB or not to 4-1BB?
Cell Mol Immunol. 2015 Jul;12(4):508-9. doi: 10.1038/cmi.2014.90. Epub 2014 Sep 8.
2
A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer.
J Immunother. 2011 Mar;34(2):175-82. doi: 10.1097/CJI.0b013e318206dac1.
3
Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.
Vaccine. 2010 Feb 3;28(5):1300-9. doi: 10.1016/j.vaccine.2009.11.020. Epub 2009 Nov 26.
4
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340.
5
Exploiting 4-1BB costimulation for enhancing antiviral vaccination.
Viral Immunol. 2006 Winter;19(4):593-601. doi: 10.1089/vim.2006.19.593.
6
Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule.
Vaccine. 2008 Jun 13;26(25):3121-34. doi: 10.1016/j.vaccine.2008.02.017. Epub 2008 Feb 22.
7
An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Vaccine. 2016 Apr 19;34(18):2147-56. doi: 10.1016/j.vaccine.2015.06.087. Epub 2016 Mar 19.
8
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.
Immunol Rev. 2009 May;229(1):192-215. doi: 10.1111/j.1600-065X.2009.00765.x.
9
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
Nat Commun. 2019 Jan 11;10(1):150. doi: 10.1038/s41467-018-08123-8.
10
HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
PLoS One. 2014 Feb 28;9(2):e90100. doi: 10.1371/journal.pone.0090100. eCollection 2014.
引用本文的文献
1
P2X7 Receptor in Dendritic Cells and Macrophages: Implications in Antigen Presentation and T Lymphocyte Activation.
Int J Mol Sci. 2024 Feb 21;25(5):2495. doi: 10.3390/ijms25052495.
2
Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.
Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165605. doi: 10.1016/j.bbadis.2019.165605. Epub 2019 Nov 15.
3
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Acta Pharmacol Sin. 2018 Feb;39(2):167-176. doi: 10.1038/aps.2017.125. Epub 2017 Sep 7.
本文引用的文献
1
Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.
Cell Mol Immunol. 2015 Jul;12(4):456-65. doi: 10.1038/cmi.2014.72. Epub 2014 Sep 8.
2
Key roles of adjuvants in modern vaccines.
Nat Med. 2013 Dec;19(12):1597-608. doi: 10.1038/nm.3409. Epub 2013 Dec 5.
3
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin.
J Exp Med. 2013 Apr 8;210(4):743-55. doi: 10.1084/jem.20121190. Epub 2013 Apr 1.
4
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
Mol Ther. 2011 Oct;19(10):1878-86. doi: 10.1038/mt.2011.145. Epub 2011 Aug 9.
5
4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
J Immunol. 2011 Aug 15;187(4):1634-42. doi: 10.4049/jimmunol.1100077. Epub 2011 Jul 8.
6
Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.
Vaccine. 2010 Feb 3;28(5):1300-9. doi: 10.1016/j.vaccine.2009.11.020. Epub 2009 Nov 26.
7
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
J Immunol. 2007 Oct 1;179(7):4910-8. doi: 10.4049/jimmunol.179.7.4910.
8
TNF/TNFR family members in costimulation of T cell responses.
Annu Rev Immunol. 2005;23:23-68. doi: 10.1146/annurev.immunol.23.021704.115839.
9
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1291-6. doi: 10.1073/pnas.0306567101. Epub 2004 Jan 26.
Zotero 插件